Mainzbiomed.com
Mainz Biomed Expands Corporate Health Program for ColoAlert …
WebBERKELEY, US – MAINZ, Germany – [April 4, 2023] — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that three German-based companies, have selected ColoAlert®, the Company’s highly efficacious and easy …
Actived: 6 days ago
Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert
WebA key component of Mainz’s U.S. regulatory strategy for ColoAlert is based on the outcome of the Company’s recently announced (February 4, 2022) launch of ColoFuture, an international clinical study evaluating the potential to integrate a portfolio of in-licensed novel mRNA biomarkers into the product. The rationale behind acquiring the
Mainz Biomed Processes First Patients from Colorectal Cancer …
WebEmployees found the online patient portal, through which they ordered the ColoAlert® test, easy-to-use and convenient. BERKELEY, US – MAINZ, Germany – May 24, 2023 —Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, …
Mainz Biomed Launches Corporate Health Program in Germany …
WebBERKELEY, US – MAINZ, Germany – January 18, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the launch of a corporate health program in Germany for ColoAlert, its highly efficacious and easy-to …
Mainz Biomed & Dante Labs Announce Partnership for the
WebDante Labs is a Global Leader in Genomics and Precision Medicine Mainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer BERKELEY, Calif. and MAINZ, Germany and New York, MAY 19, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics …
Dr. Heiner Dreismann (Investors Page)
WebABOUT US DR. HEINER DREISMANN Chairman & Non Executive Director Former President and CEO of Roche Molecular Systems, Pleasanton, California (2000-2006). Past member of Roche’s Global Diagnostic and Executive Committee, and head of global business development, Over 35 years of experience in the life sciences and health care …
Mainz Biomed Partners with Liquid Biosciences to Harness the …
WebCollaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing BERKELEY, US – MAINZ, Germany – NOVEMBER 9, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, …
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: …
WebBERKELEY, US – MAINZ, Germany – March 12 th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its upcoming participation at the 39th UDH Congress 2024, taking place on March 16th & 17th in …
Mainz Biomed Partners with Trusted Health Advisors to Support …
WebJay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaboration Mainz Biomed’s Pivotal FDA PMA clinical trial (ReconAAsense) evaluating gold standard self-administered colorectal cancer screening test on track to commence patient …
Mainz Biomed Reports Third Quarter 2023 Financial Results and …
WebColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023 ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 80% BERKELEY, US – MAINZ, Germany – November …
Mainz Biomed Appoints Michele Pedrocchi, Former Head of Roche
WebBERKELEY, US – MAINZ, Germany – JANUARY 12th, 2022 — Mainz Biomed N.V. (NASDAQ: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Michele Pedrocchi to its Strategic Advisory Board. “Having Michele …
Mainz Biomed startet Programm zur Unterstützung der …
WebDie Initiative zur Gesundheitsversorgung adressiert einen Markt mit einem jährlichen Volumen von 1 Milliarde Euro in Deutschland BERKELEY, US – MAINZ, Deutschland – 18. Januar 2023 —Mainz Biomed NV (NASDAQ:MYNZ) („Mainz Biomed” oder „das Unternehmen”), ein molekulargenetisches Diagnostikunternehmen, das sich …
Top Categories
Popular Searched
› Austin health sciences insurance
› Mingo county wv health department
› Simply healthcare precert lookup
› Meghalaya health systems project
› Employee health clinics forum
› Tata aig health insurance age
› Problem solving in health care examples
› Section 14 health plan report
Recently Searched
› Peacehealth clinic florence fl
› Greater good health linkedin
› Spectrum health grand rapids ny
› Alameda department of environmental health
› Grace health customer service number
› Wayne unc health care facebook
› Cook county health englewood hospital
› Tampa family health dale mabry